Integrum appoints Blake E. Pokress as Vice President of North America

Report this content

Integrum, a leading provider of innovative solutions for bone anchored prosthetics, is today proud to announce the appointment of Blake E. Pokress as its Vice President of North America.

Blake will be instrumental in leading the overall growth of Integrum’s OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) implant system and maximizing the unprecedented opportunity to improve the lives of the millions of people living with limb loss in North America.

With more than twelve years of orthopaedic experience, Blake will drive increased awareness and understanding of Integrum’s solutions with key healthcare and academic stakeholders across the U.S. and North America.

“We are very happy to have Blake join us to strengthen our team and our presence in the hugely important North American market,” said Rutger Barrdahl, CEO at Integrum. “Blake is a seasoned sales manager with a proven history of selling innovative medical concepts and building relationships in the healthcare industry.”

Integrum’s OPRA implant system is the only FDA-approved, bone anchored prosthetic solution available in the United States.  OPRA consists of an anchorage element (fixture) and a skin penetrating device (abutment).  The fixture is surgically inserted into the bone and, after a healing period, the abutment is connected to the fixture.  The prosthetic limb is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.  

For more information, please contact:

Rutger Barrdahl, CEO
Tel. +46 705 23 39 55

Certified Adviser:
Erik Penser Bank AB
Tel. +46 8 463 8000

About Integrum 

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over almost three decades from 500 surgeries in 13 countries has led to the development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the U.S. under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA approved technology for bone anchored prosthetics available in the U.S. More information on the company and its innovative solutions for amputees can be found at






We are very happy to have Blake join us to strengthen our team and our presence in the hugely important North American market.
Rutger Barrdahl, CEO at Integrum